Insights
Humana Inc. Q1 2026 Earnings Call Insight
The most important signal from Humana’s Q1 2026 results is not the headline EPS but the explicit strategy being telegraphed for 2027 bids: benefit cuts are coming.
April 29, 2026
Analysis, playbooks, and research for government-sponsored health plans navigating a faster, more competitive market.
The most important signal from Humana’s Q1 2026 results is not the headline EPS but the explicit strategy being telegraphed for 2027 bids: benefit cuts are coming.
Centene’s Q1 2026 results landed roughly $0.50 ahead of its own internal expectations, with adjusted EPS of $3.37 and a 58% beat over Street consensus.
The most significant finding from UnitedHealth Group’s Q1 2026 results is not the beat itself—it is what the beat signals about the trajectory of the turnaround.
The most significant and surprising finding in Molina Healthcare’s Q1 2026 results is not the EPS beat—it is the explicit reversal of the 2025 acuity shift that destroyed earnings for the sector.
CVS Health delivered Q4 2025 adjusted EPS of $1.09, beating consensus of $1.00, on revenue of $105.7B (up 8.2% YoY). Full year 2025 adjusted EPS of $6.75 exceeded initial guidance on revenue of $402.1B (up 7.8%).
Molina Healthcare reported a Q4 2025 adjusted loss of $2.75 per share versus expectations of $0.34 EPS, a 909% miss that triggered a 30% premarket stock decline. The miss was driven by $2.00/share of unexpected California retroactive premium adjustments and persistent medical cost trend pressure across Medicare and Marketplace.
The healthcare payer industry is changing rapidly—and our resources help you stay on top of it all. Sign up to get new insights, success stories, and more, sent right to your inbox.